Phase II Randomised Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.

PHASE2UnknownINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 31, 2020

Study Completion Date

January 31, 2021

Conditions
Multiple Myeloma
Interventions
DRUG

Ixazomib

Chemotherapy

DRUG

Cyclophosphamide

Chemotherapy

DRUG

Dexamethasone

Chemotherapy

Trial Locations (18)

B15 2TH

Queen Elizabeth Medical Centre, Birmingham

B9 5ST

Heart of England NHS Foundation Trust, Birmingham

BH7 7DW

Royal Bournemouth General Hospital, Bournemouth

BS1 3NU

University Hospital Bristol NHS Foundation Trust, Bristol

TS24 9AH

North Tees and Hartlepool NHS Foundation Trust, Hartlepool

LS9 7TF

Leeds Teaching Hospitals NHS Trust, Leeds

L7 8XP

Royal Liverpool and Broadgreen University Hospital NHS Trust, Liverpool

E1 1BB

Barts and the London NHS Trust, London

NW1 2PG

University College London Hospitals NHS Foundation Trust, London

SE1 9RT

Guy's and St Thomas's NHS Foundation Trust, London

SW3 6JJ

Royal Marsden Hospital, London

W2 1NY

Imperial College Healthcare NHS Trust, London

M20 4BX

The Christie NHS Foundation Trust, Manchester

NG7 2UH

Nottingham University Hospital NHS Trust, Nottingham

OX3 7LE

Churchill Hospital, Oxford

S5 7AU

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield

SO16 6YD

Southampton University Hospital NHS Trust, Southampton

WV10 0QP

The Royal Wolverhampton Hospital NHS Trust, Wolverhampton

Sponsors
All Listed Sponsors
collaborator

Myeloma UK

OTHER

collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

University of Leeds

OTHER